ArticleClinical case reports2026
A Novel Treatment Schedule Combining Injectable Platelet-Rich Fibrin and Endolift Laser for Facial Rejuvenation: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of Endolift laser therapy and injectable platelet-rich fibrin (i-PRF) is an emerging strategy in aesthetic medicine, but the optimal scheduling of these modalities remains unexplored. This case report highlights a novel treatment schedule combining i-PRF and Endolift laser therapy, resulting in noticeable short-term facial rejuvenation in a 56-year-old female. A 56-year-old woman presented with concerns regarding facial skin laxity and aging. A unique treatment schedule was implemented: i-PRF injections were administered 1 day before (Day -1), 1 week after (Day +7), and 1 month after (Day +30) a single Endolift laser session (Day 0). At the 4-week follow-up, the patient demonstrated marked improvement in skin tightness, texture, and overall facial appearance, as assessed by clinical examination, standardized photography, and high patient-reported satisfaction. Only mild, transient adverse effects were observed, with no delayed complications. This novel schedule combining i-PRF and the Endolift laser demonstrates promising synergistic effects, resulting in significant short-term skin rejuvenation. While these initial findings suggest that the precise timing of i-PRF enhances the regenerative impact of Endolift therapy, further large-scale studies utilizing objective measurement scales and extended follow-up periods (3-6 months) are warranted to validate long-term durability and establish standardized protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.